Semaglutide: A Research Overview of the GLP-1 Receptor Agonist

Semaglutide is the compound at the center of the metabolic-medicine story of the decade. It is the once-weekly GLP-1 receptor agonist marketed as Ozempic and Rybelsus for type 2 diabetes and as Wegovy for obesity, and it is among the most extensively trialed peptide drugs in modern medicine. Unlike most compounds in this library, its evidence base is not a matter of debate — it is FDA-approved, backed by large randomized trials with hard clinical endpoints, and prescribed to millions.

That is exactly why the most important distinction here is not scientific but practical: the approved medicine and the “research-grade” semaglutide sold online are not the same thing. This overview summarizes what the published literature and regulatory record report about semaglutide — its structure, mechanism, evidence, status, and safety. It describes findings as they appeared in their study populations. It is not dosing guidance, medical advice, or a recommendation for use.

What Semaglutide Is

Semaglutide is a peptide analogue of the human incretin hormone glucagon-like peptide-1 (GLP-1), sharing roughly 94% of its sequence (mechanism and structure, StatPearls). It was engineered from native GLP-1 with a small number of deliberate changes: a substitution at position 8 that resists breakdown by the enzyme DPP-4, and a fatty-diacid chain attached to the peptide that binds tightly to blood albumin. That albumin binding is what slows its clearance and gives it a half-life of about one week, enabling once-weekly injection (discovery and design of semaglutide, J Med Chem). An oral tablet formulation (Rybelsus), co-formulated with an absorption enhancer, delivers the same molecule by mouth.

Mechanism — A GLP-1 Receptor Agonist

Semaglutide activates the GLP-1 receptor, reproducing and prolonging the effects of the body’s own incretin signaling. Its reported actions are glucose-dependent: it enhances insulin secretion when blood glucose is elevated, suppresses inappropriate glucagon release, slows gastric emptying, and acts on GLP-1 receptors in the hypothalamus to reduce hunger and increase satiety (mechanism of action, StatPearls). The glucose-dependence of the insulin effect is why, used on its own, it carries a relatively low risk of hypoglycemia. The appetite and gastric effects are the basis of the weight reduction that made it a landmark obesity therapy.

The Clinical Evidence — Large and Replicated

Semaglutide’s evidence base is among the strongest for any compound discussed on this site, spanning glycemic control, weight, cardiovascular events, and liver disease:

• Type 2 diabetes. The SUSTAIN and PIONEER trial programs established semaglutide’s glucose-lowering efficacy, supporting the 2017 approval of injectable Ozempic and the 2019 approval of the first oral GLP-1, Rybelsus (Rybelsus approval history, Drugs.com).
• Obesity. In the phase 3 STEP 1 trial, once-weekly semaglutide 2.4 mg produced a mean weight loss of about 14.9% over 68 weeks, versus 2.4% on placebo, with the large majority of participants losing at least 5% of body weight (STEP 1, NEJM). This underpinned the 2021 approval of Wegovy.
• Cardiovascular disease. The SELECT trial randomized 17,604 adults with overweight or obesity and established cardiovascular disease but without diabetes; semaglutide reduced major adverse cardiovascular events by 20% (hazard ratio 0.80) — the first weight-management drug to demonstrate this (SELECT, NEJM).
• Liver disease (MASH). In August 2025, on the strength of the phase 3 ESSENCE trial, the FDA approved Wegovy for adults with non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with moderate-to-advanced fibrosis — the first GLP-1 agonist to carry an approved liver indication (Wegovy MASH approval, Novo Nordisk).

Semaglutide 2.4 mg−14.9%

Placebo−2.4%

Source: Wilding et al., STEP 1, New England Journal of Medicine, 2021. Bar length is relative to the larger value.

Status — FDA-Approved (and the Gray-Market Caveat)

Semaglutide is FDA-approved and widely prescribed under three brand names: Ozempic (injectable, type 2 diabetes and cardiovascular risk reduction), Rybelsus (oral, type 2 diabetes), and Wegovy (injectable, chronic weight management, cardiovascular risk reduction, and non-cirrhotic MASH) (approved indications, StatPearls). This is what places it in Tier I of this library.

The essential caveat is that this approval attaches to the specific, quality-controlled medicines made by their manufacturer — not to vials of “semaglutide” sold online for research. Material sold that way is not the approved drug: it is not FDA-approved, is typically labeled for in vitro research use only and not for human consumption, and carries no guarantee of identity, purity, or dose. The trial results summarized above were generated with the approved product under medical supervision and cannot be assumed to transfer to unregulated material used outside that context.

Safety Considerations

Semaglutide’s safety profile is well characterized. Its most common adverse effects are gastrointestinal — nausea, vomiting, diarrhea, constipation, and abdominal pain — reported by a substantial fraction of users, particularly at higher (weight-management) doses (adverse effects, StatPearls). It carries an FDA boxed warning for thyroid C-cell tumors, based on dose- and duration-dependent tumors in rodents; it is contraindicated in people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2. Other recognized risks include pancreatitis, gallbladder disease, acute kidney injury from dehydration secondary to GI symptoms, possible worsening of diabetic retinopathy with rapid glucose improvement, and an increased hypoglycemia risk when combined with insulin or sulfonylureas. These are precisely the risks that clinical supervision is designed to manage — supervision that is absent when unregulated material is used outside of care.

Why Semaglutide Draws Research Interest

Semaglutide reset expectations for what a metabolic drug could do: meaningful, sustained weight loss from a single weekly injection, followed by proof that the same molecule reduces heart attacks, strokes, and — most recently — liver fibrosis. Its accurate framing is an approved, extensively trialed medicine with replicated hard-endpoint evidence across four disease areas, a well-defined safety profile, and a clear line between the regulated product and the unregulated material sold under its name.

For deeper reading, the cited peer-reviewed trials are the best starting point. Semaglutide is best understood alongside the other incretin agents — see the tirzepatide (approved dual GIP/GLP-1 agonist), retatrutide (investigational triple agonist), and cagrilintide overviews — and the wider class is collected in our peptide research library.